Morphine

Generic Name: Morphine

Brand Names: Arymo, Avinza, Doloral, Duramorph, Embeda, Infumorph, Kadian, M-ediat, M-eslon, MSIR, Mitigo, Ms Contin, Statex

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₉NO_₃

CAS Number: 57-27-2

Unique Ingredient Identifier: 76I7G6D29C

Background: Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as codeine, fentanyl, methadone, hydrocodone, hydromorphone, meperidine, and oxycodone.

Morphine was granted FDA approval in 1941.

Indication: Morphine is used for the management of chronic, moderate to severe pain.

Opiods, including morphine, are effective for the short term management of pain. Patients taking opioids long term may need to be monitored for the development of physical dependence, addiction disorder, and drug abuse.

Associated Conditions: Chronic Pain, Severe Pain

Associated Therapies: -

Clinical Trials

ANalgesic Efficacy and Safety of MOrphiNe Versus Methoxyflurane in Patients With Acute Myocardial Infarction

Phase 3

Recruiting

Conditions: ST Elevation Myocardial Infarction
Non ST Segment Elevation Acute Coronary Syndrome

Interventions: Drug: Methoxyflurane - Penthrox
Drug: Morphine

First Posted Date: 2020-07-17

Last Posted Date: 2023-09-11

Lead Sponsor: Collegium Medicum w Bydgoszczy

Target Recruit Count: 200

Registration Number: NCT04476173

Locations: 🇵🇱
Department of Cardiology, Bydgoszcz, Kujawsko-Pomorskie, Poland

Methadone in Cystectomy Patients

Not Applicable

Completed

Conditions: Pathologic Processes
Neurologic Manifestations
Pain, Postoperative
Pain
Postoperative Complications
Bladder Cancer
Signs and Symptoms
Neurologic Symptoms
Side Effect of Drug

Interventions: Drug: Methadone
Drug: Morphine

First Posted Date: 2020-07-17

Last Posted Date: 2023-09-13

Lead Sponsor: University of Aarhus

Target Recruit Count: 114

Registration Number: NCT04475029

Locations: 🇩🇰
Aarhus University Hospital, Aarhus, Denmark

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ASP8062 With a Single Dose of Morphine in Recreational Opioid Using Participants

Phase 1

Completed

Conditions: Opioid Use Disorder

Interventions: Drug: ASP8082
Drug: Placebo
Drug: morphine

First Posted Date: 2020-06-26

Last Posted Date: 2024-11-21

Lead Sponsor: Astellas Pharma Global Development, Inc.

Target Recruit Count: 24

Registration Number: NCT04448561

Locations: 🇺🇸
Altasciences Clinical Kansas, Inc., Overland Park, Kansas, United States

Efficacy of Dexmedetomidine Versus Morphine as an Adjunct to Bupivacaine in Caudal Anesthesia.

Not Applicable

Completed

Conditions: Anesthesia, Local

Interventions: Drug: Dexmedetomidine
Drug: Morphine

First Posted Date: 2020-06-24

Last Posted Date: 2020-12-22

Lead Sponsor: Cairo University

Target Recruit Count: 50

Registration Number: NCT04445636

Locations: 🇪🇬
Cairo University Hospitals, Cairo, Egypt

Morphine Sulfate/Placebo for the Treatment of PulmonAry Fibrosis Cough

Phase 3

Completed

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: Placebo oral tablet
Drug: Morphine Sulfate

First Posted Date: 2020-06-12

Last Posted Date: 2023-04-14

Lead Sponsor: Royal Brompton & Harefield NHS Foundation Trust

Target Recruit Count: 44

Registration Number: NCT04429516

Locations: 🇬🇧
Royal Brompton Hospital, London, United Kingdom

Intraosseous Morphine in Primary TKA

Phase 4

Completed

Conditions: Knee Disease
Arthritis Knee
Pain, Acute

Interventions: Drug: Morphine

First Posted Date: 2020-05-14

Last Posted Date: 2021-07-07

Lead Sponsor: The Methodist Hospital Research Institute

Target Recruit Count: 48

Registration Number: NCT04388111

Locations: 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States

Brain Effects of Opiate Agonist and Antagonist

Phase 4

Completed

Conditions: Chronic Low-back Pain

Interventions: Drug: Morphine

First Posted Date: 2020-04-10

Last Posted Date: 2021-05-07

Lead Sponsor: University of Rochester

Target Recruit Count: 10

Registration Number: NCT04342130

Locations: 🇺🇸
Yale University, New Haven, Connecticut, United States

Different Treatment Modalities in the Management of the Painful Crisis in Pediatric Sickle- Cell Anemia

Phase 2

Completed

Conditions: Vaso-occlusive Crisis
Sickle Cell Disease
Sickle Cell Anemia in Children

Interventions: Drug: Vit D
Drug: Omega 3
Drug: Statins (Cardiovascular Agents)
Drug: Zinc sulfate
Drug: Hydroxy Urea
Drug: Folic Acid Supplementation
Drug: Morphine Sulfate
Procedure: blood transfusion session

First Posted Date: 2020-03-10

Last Posted Date: 2021-01-27

Lead Sponsor: Beni-Suef University

Target Recruit Count: 350

Registration Number: NCT04301336

Locations: 🇪🇬
Faculty of Pharmacy, Beni-Suef university, Banī Suwayf, Egypt
🇪🇬
Health insurance hospital, Banī Suwayf, Egypt
🇪🇬
Faculty of medicine, Beni-suef univeristy - Beni-Seuf university hospital, Banī Suwayf, Egypt

and more 1 locations